明亮听芹
Lv2
130 积分
2024-01-01 加入
-
First-Line Treatment With Mitoxantrone, Methotrexate, Vincristine, and Carboplatine (MIMOC) Plus Cyclical Hormonotherapy With Tamoxifen and Megestrol Acetate in Advanced Breast Cancer
5天前
已关闭
-
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
5天前
已关闭
-
Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization
4个月前
已完结
-
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
5个月前
已完结
-
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
6个月前
已完结
-
P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial
6个月前
已关闭
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
-
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
6个月前
已关闭
-
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
7个月前
已完结